HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

R 306465

inhibits HDAC1; structure in first source

Also Known As:

R-306465; R306465

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Andries, L: 1 article (11/2007)
2.	Angibaud, P: 1 article (11/2007)
3.	Arts, J: 1 article (11/2007)
4.	Floren, W: 1 article (11/2007)
5.	Geerts, T: 1 article (11/2007)
6.	Janicot, M: 1 article (11/2007)
7.	Janssen, L: 1 article (11/2007)
8.	Janssens, B: 1 article (11/2007)
9.	Johnson, D L: 1 article (11/2007)
10.	Jung, M: 1 article (11/2007)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 11/19/2007 - "R306465 potently inhibited cell proliferation of all main solid tumour indications, including ovarian, lung, colon, breast and prostate cancer cell lines, with IC50 values ranging from 30 to 300 nM. Haematological cell lines, including acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphoblastic leukaemia, chronic myeloid leukaemia, lymphoma and myeloma, were potently inhibited at a similar concentration range. "
2.	Neoplasms (Cancer) 11/19/2007 - "The high activity of R306465 in cell-based assays and in vivo after oral administration makes R306465 a promising novel antitumoral agent with potential applicability in a broad spectrum of human malignancies." 11/19/2007 - "R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies." 11/19/2007 - "R306465 is a novel hydroxamate-based histone deacetylase (HDAC) inhibitor with broad-spectrum antitumour activity against solid and haematological malignancies in preclinical models. "
3.	Lymphoma (Lymphomas) 11/19/2007 - "R306465 potently inhibited cell proliferation of all main solid tumour indications, including ovarian, lung, colon, breast and prostate cancer cell lines, with IC50 values ranging from 30 to 300 nM. Haematological cell lines, including acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphoblastic leukaemia, chronic myeloid leukaemia, lymphoma and myeloma, were potently inhibited at a similar concentration range. "
4.	Carcinoma (Carcinomatosis) 11/19/2007 - "Once-daily oral administration of R306465 at well-tolerated doses inhibited the growth of A2780 ovarian, H460 lung and HCT116 colon carcinomas in immunodeficient mice. "

Related Drugs and Biologics

1.	Histone Deacetylase Inhibitors
2.	Histone Deacetylases (Histone Deacetylase)

Related Therapies and Procedures

1.	Oral Administration